Overview

Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia

Status:
Terminated
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
This study will collect data on safety, effectiveness and patient acceptance of MabCampath treatment under daily life conditions.
Details
Lead Sponsor:
Genzyme, a Sanofi Company
Treatments:
Alemtuzumab